Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 223 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Conjunctivitis Clear all
Not listed Early Phase 1 Interventional

To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

NCT03975374
View directory record Official record
Conditions
Blepharo Conjunctivitis
Interventions
Tobramycin/dexamethasone opthalmic solution, Tobradex Opthalmic Solution
Drug
Lead sponsor
Sutphin Drugs
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 2, 2026, 5:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft

NCT01339507
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
Cunningham, Derek N., O.D., P.A.
Individual
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis

NCT00432757
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen with a Contact Lens (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Los Angeles, California • Charlotte, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

NCT05636228
View directory record Official record
Conditions
Acute Infectious Keratoconjunctivitis
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Glendale, California • Pasadena, California • Largo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878
View directory record Official record
Conditions
Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions
Lifitegrast
Drug
Lead sponsor
EV Clinical Trials
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

NCT01817582
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Lotemax, Restasis, Soothe® Lubricant Eye Drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02688556
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine, vehicle of OTX-101
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Rancho Cordova, California • Edgewood, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

NCT01289431
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Mapracorat, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

NCT00972777
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Besifloxacin, Vehicle (Placebo)
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Year and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Sep 2, 2026, 5:46 AM EDT
Completed No phase listed Observational

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

NCT00982163
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Sep 2, 2026, 5:46 AM EDT
Not listed Phase 1 Interventional

Airway Immune Response to Allergens (Use Lay Language Here)

NCT04619017
View directory record Official record
Conditions
Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Segmental allergen challenge
Biological
Lead sponsor
JOSALYN CHO
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 2, 2026, 5:46 AM EDT
Completed No phase listed Observational

Screening for NEI Clinical Studies

NCT00001734
View directory record Official record
Conditions
Conjunctivitis, Iritis, Keratitis, Retinitis, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

NCT03706443
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases, Keratoconjunctivitis, Eye Diseases, Keratitis, Corneal Disease, Ophthalmic Solution
Interventions
Systane Complete, Systane Ultra
Other
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

NCT01639846
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
RX-10045, Vehicle for RX-10045 arm
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

NCT00411827
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
PRK with conjunctival impression cytology before and after surgery, LASIK with conjunctival impression cytology before and after surgery
Procedure
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
21 Years to 40 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

Moxifloxacin vs. Polytrim for Conjunctivitis

NCT00581542
View directory record Official record
Conditions
Conjunctivitis
Interventions
moxifloxacin, polytrim
Drug
Lead sponsor
University of Rochester
Other
Eligibility
1 Year to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

NCT00464438
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
gatifloxacin, moxifloxacin 0.5% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
Up to 31 Days
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 1 Interventional

Systemic Pharmacokinetics of BOL-303224-A

NCT00407589
View directory record Official record
Conditions
Conjunctivitis, Bacterial
Interventions
BOL-303224-A
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome

NCT02680158
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal, Sham, Oculeve Extranasal
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Waterbury, Connecticut • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 2, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

AL-15469A for the Treatment of Bacterial Conjunctivitis

NCT00332293
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Month and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 2, 2026, 5:46 AM EDT